StoxOnesource Specialty Pharma vs Cohance Lifesciences: share price & financials comparison
NSE: ONESOURCE vs COHANCE · Healthcare · as of 06 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Onesource Specialty Pharma vs Cohance Lifesciences at a glance
Onesource Specialty Pharma (ONESOURCE) has a market capitalisation of ₹18,345 Cr, against ₹16,588 Cr for Cohance Lifesciences (COHANCE). Over the past year Onesource Specialty Pharma has returned -13.7%, compared with -44.9% for Cohance Lifesciences. Cohance Lifesciences earns a higher return on equity (2.7% vs -0.0%). Onesource Specialty Pharma comes out ahead on valuation, growth and momentum. Cohance Lifesciences comes out ahead on size, profitability, financial health and technicals. Across the scored metrics below, Onesource Specialty Pharma leads on 7 and Cohance Lifesciences on 5. On StoxGud's 10-point checklist, Onesource Specialty Pharma scores 4/10 and Cohance Lifesciences scores 3/10.
| Metric | Onesource Specialty Pharma | Cohance Lifesciences |
|---|---|---|
| Size | ||
| Market cap | ₹18,345 Cr | ₹16,588 Cr |
| Revenue (latest FY) | ₹1,422 Cr | ₹2,269 Cr |
| Net profit (latest FY) | ₹-74 Cr | ₹179 Cr |
| Valuation | ||
| P/E | — | 156.1 |
| P/B | 3.10 | 4.24 |
| Profitability | ||
| Return on equity | 0.0% | 2.7% |
| Net profit margin | -0.1% | 5.0% |
| Operating margin | 23.5% | 14.8% |
| Growth | ||
| Revenue growth (YoY) | +37.4% | -23.1% |
| Net profit growth (YoY) | +687.0% | -149.3% |
| Revenue CAGR (multi-year) | — | +18.2% |
| Financial health | ||
| Debt to equity | 0.25 | 0.04 |
| Momentum | ||
| 1-month return | +4.7% | -4.8% |
| 1-year return | -13.7% | -44.9% |
| 3-year CAGR | — | -8.8% |
| 5-year CAGR | — | -2.9% |
| Distance from 52W high | -14.8% | -44.3% |
| Technicals | ||
| RSI (14) | 71 | 39 |
| Price vs 200-day avg | +3.2% | +5.9% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Onesource Specialty Pharma | Cohance Lifesciences |
|---|---|---|
| Price above 50-day average | ✓ | ✗ |
| Price above 200-day average | ✓ | ✓ |
| 50-day average above 200-day (uptrend) | ✗ | ✓ |
| RSI in healthy 40–70 zone | ✗ | ✗ |
| Positive 1-year return | ✗ | ✗ |
| Return on equity above 15% | ✗ | ✗ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✓ | ✗ |
| Net profit margin above 10% | ✗ | ✗ |
| P/E below industry median | ✗ | ✗ |
| Score | 4/10 | 3/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Onesource Specialty Pharma or Cohance Lifesciences?
Onesource Specialty Pharma has a market cap of ₹18,345 Cr and Cohance Lifesciences has a market cap of ₹16,588 Cr as of 06 Nov 2026.
Which gave better returns in the last year, Onesource Specialty Pharma or Cohance Lifesciences?
Onesource Specialty Pharma did better: Onesource Specialty Pharma returned -13.7% and Cohance Lifesciences returned -44.9% over one year.
Is Onesource Specialty Pharma or Cohance Lifesciences a better buy?
StoxGud does not give buy or sell recommendations. On our rules-based checklist Onesource Specialty Pharma scores 4/10 and Cohance Lifesciences scores 3/10; compare valuation, profitability, growth and momentum above and consult a SEBI-registered adviser.